scholarly journals Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5610
Author(s):  
Tim Wende ◽  
Johannes Kasper ◽  
Gordian Prasse ◽  
Änne Glass ◽  
Thomas Kriesen ◽  
...  
Keyword(s):  
Prognostic Marker ◽  
Muscle Thickness ◽  
Proportional Hazard ◽  
Newly Diagnosed ◽  
University Hospitals ◽  
Temporal Muscle ◽  
Independent Prognostic Marker ◽  
Calculation Results ◽  
Newly Diagnosed Glioblastoma ◽  
Multivariate Proportional Hazard

Background: Reduced temporal muscle thickness (TMT) has been discussed as a prognostic marker in IDH-wildtype glioblastoma. This retrospective multicenter study was designed to investigate whether TMT is an independent prognostic marker in newly diagnosed glioblastoma. Methods: TMT was retrospectively measured in 335 patients with newly diagnosed glioblastoma between 1 January 2014 and 31 December 2019 at the University Hospitals of Leipzig and Rostock. The cohort was dichotomized by TMT and tested for association with overall survival (OS) after 12 months by multivariate proportional hazard calculation. Results: TMT of 7.0 mm or more was associated with increased OS (46.3 ± 3.9% versus 36.6 ± 3.9%, p > 0.001). However, the sub-groups showed significant epidemiological differences. In multivariate proportional hazard calculation, patient age (HR 1.01; p = 0.004), MGMT promoter status (HR 0.76; p = 0.002), EOR (HR 0.61), adjuvant irradiation (HR 0.24) and adjuvant chemotherapy (HR 0.40; all p < 0.001) were independent prognostic markers for OS. However, KPS (HR 1.00, p = 0.31), BMI (HR 0.98, p = 0.11) and TMT (HR 1.06; p = 0.07) were not significantly associated with OS. Conclusion: TMT has not appeared as a statistically independent prognostic marker in this cohort of patients with newly diagnosed IDH-wildtype glioblastoma.

scholarly journals Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases

2018 ◽  
Vol 140 (1) ◽  
pp. 173-178 ◽  
Author(s):  
Julia Furtner ◽  
Anna S. Berghoff ◽  
Veronika Schöpf ◽  
Robert Reumann ◽  
Benjamin Pascher ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Prognostic Marker ◽  
Muscle Thickness ◽  
Newly Diagnosed ◽  
Temporal Muscle ◽  
Independent Prognostic Marker ◽  
Melanoma Patients

OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii7-ii7
Author(s):  
J Furtner ◽  
M Weller ◽  
M Weber ◽  
T Gorlia ◽  
B Nabors ◽  
...  
Keyword(s):  
At Risk ◽  
Muscle Mass ◽  
Muscle Thickness ◽  
Rank Test ◽  
Newly Diagnosed ◽  
Normal Muscle ◽  
Cox Models ◽  
Temporal Muscle ◽  
Patients At Risk ◽  
Newly Diagnosed Glioblastoma

Abstract BACKGROUND Temporal muscle thickness (TMT) was described as surrogate parameter of skeletal muscle mass. This study aimed to investigate the prognostic relevance of TMT in patients with newly diagnosed glioblastoma. MATERIAL AND METHODS TMT was assessed in cranial magnetic resonance images (MRI) of 755 pts enrolled in the CENTRIC EORTC 26071-22072 study (n=508) and CORE study (n=247). Predefined sex-specific TMT cutoff values were used to categorize “patients at risk of sarcopenia” and “patients with normal muscle status” at baseline. Furthermore, patients were categorized according to the extent of TMT loss over time. Cox models adjusted for other explanatory variables were used to evaluate the associations with progression-free survival (PFS) and overall survival (OS). RESULTS Overall, 510/755 (67.6%) patients were categorized as “at risk of sarcopenia” and 245/755 (32.4%) patients had normal muscle status at baseline. In both study cohorts patient at risk of sarcopenia at baseline had significantly higher risk of progression and death than patients with normal muscle status (CENTRIC: PFS = HR 0.16, 95% CI: 0.12, 0.21, p&lt;0.001; OS = HR 0.341, 95% CI: 0.27, 0.44, p &lt; 0.001; CORE: PFS = HR 0.29, 95% CI: 0.21, 0.39, p&lt;0.001; OS = HR 0.365, 95% CI: 0.27, 0.49, p&lt;0.001). In multivariate Cox models adjusted for other important prognostic parameters similar results were obtained. In patients at risk for sarcopenia the extent of TMT loss over time showed a significant inverse correlation with median OS times (CENTRIC: p &lt; 0.001, CORE: p = 0.005, log-rank test), but not in patients with normal baseline muscle mass in both study cohorts (CENTRIC: p = 0.538, CORE: p = 0.28, log-rank test). CONCLUSION TMT identifies patients with newly diagnosed glioblastoma at risk for progressive sarcopenia and adverse outcomes. Early intervention for muscle mass preservation including exercise and resistance training as well as nutritional support may prevent skeletal muscle loss and improve patient outcome in this group of patients.

scholarly journals Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma

2020 ◽  
Author(s):  
Geon An ◽  
Stephen Ahn ◽  
Jae-Sung Park ◽  
Sin-Soo Jeun ◽  
Yong-Kil Hong
Keyword(s):  
Clinical Outcomes ◽  
Medical Records ◽  
Muscle Thickness ◽  
Progression Free Survival ◽  
Newly Diagnosed ◽  
Eligibility Criteria ◽  
Temporal Muscle ◽  
Free Survival ◽  
Newly Diagnosed Glioblastoma ◽  
Preclinical And Clinical Studies

Purpose Temporal muscle thickness (TMT) has been suggested as a novel biomarker that can represent sarcopenia in head and neck malignancies. This study investigated the association of TMT with clinical outcomes in patients with newly diagnosed glioblastoma (GBM). Materials and Methods Using electronic medical records, all GBM patients between 2008 and 2018 at Seoul St. Marys Hospital were reviewed. Total 177 patients met our eligibility criteria. Results The thinner group who had TMT less than the median showed shorter overall survival (OS) and progression-free survival (PFS) than the thicker group who had TMT more than median (OS; 11.0 versus 18.0 months, p < 0.001, and PFS; 6.0 versus 11.0 months, p < 0.001). In the multivariate analysis, the thinner group had negative associations with OS and PFS (OS; HR 2.63 (1.34-2.63), p < 0.001, and PFS; HR 2.21 (1.34-2.50), p = 0.002). We also performed propensity score matching between the thinner and thicker groups to minimize the potential bias. The thinner group showed shorter OS and PFS (OS; 13.5 versus 19.0 months, p = 0.006, and PFS; 6.5 versus 9.0 months, p = 0.028) and had negative associations with OS and PFS than the thicker group (OS; HR 1.90 (1.19-3.03), p = 0.008, and PFS; HR 1.70 (1.07-2.70), p = 0.026) in matched patients. Conclusion Our findings suggest that TMT can be a useful prognostic biomarker for clinical outcomes in GBM patients. Further preclinical and clinical studies could help elucidate this association of sarcopenia with clinical outcomes in GBM patients.

scholarly journals Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Xiao-Meng Dai ◽  
Tao Huang ◽  
Sheng-Li Yang ◽  
Xiu-Mei Zheng ◽  
George G. Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Marker ◽  
Tumor Biology ◽  
Proportional Hazard ◽  
Independent Prognostic Marker ◽  
Cox Proportional Hazard ◽  
Good Target ◽  
B Virus ◽  
Cox Proportional Hazard Regression ◽  
Curative Hepatectomy

Accumulating evidence suggests that the tumor microenvironment has a profound influence on tumor initiation and progression, opening a new avenue for studying tumor biology. Nonetheless, the prognostic values of the peritumoral expression of EpCAM and CD13 remain to be elucidated in hepatocellular carcinoma (HCC) patients. In this study, the expression of EpCAM and CD13 was assessed by immunohistochemistry in peritumoral liver hepatocytes from 106 hepatitis B virus- (HBV-) related HCC patients who had undergone curative hepatectomy. The peritumoral EpCAM-positive group had a significantly worse overall survival (OS) (p=0.003) and recurrence-free survival (RFS) (p=0.022) compared to the negative group. Peritumoral CD13-positive patients were also associated with poor OS (p=0.038), while not significantly associated with RFS. The adjusted multivariate COX proportional hazard regression analysis suggested that only the positive expression of peritumoral EpCAM precisely predicted poor OS. Being peritumoral EpCAM positive was also significantly associated with a larger tumor size, liver cirrhosis, and more frequent vascular invasion; however, no statistically significant association was observed between CD13 and any clinicopathological features. Taken together, peritumoral EpCAM and CD13 expression was associated with a poor prognosis, but EpCAM may be a better prognostic marker than CD13 in HBV-related HCC patients. In the future, peritumoral EpCAM could be a good target for adjuvant therapy after curative hepatectomy.

scholarly journals Prognostic value of preoperative inflammatory markers in patients with different molecular subgroups of WHO grade II and III diffuse gliomas

2019 ◽  
Author(s):  
Zengxin Qi ◽  
Jiajun Cai ◽  
Xiangda Meng ◽  
Shengyong Cai ◽  
Chao Tang ◽  
...  
Keyword(s):  
Prognostic Marker ◽  
Diffuse Glioma ◽  
Newly Diagnosed ◽  
Wild Type ◽  
Who Grade ◽  
Independent Prognostic Marker ◽  
Diffuse Gliomas ◽  
Grade Ii ◽  
Prognostic Implications

Abstract Objective: To determine the prognostic implications of these immune indices in WHO Grade II & III gliomas and different molecular subgroups.Methods : Clinical data from 214 newly diagnosed WHO grade II and III diffuse glioma patients were studied retrospectively. Cut-off values were determined by X-tile software. IDH and TERT promotor mutations were detected by gene sequencing, and 1p19q co-deletion was estimated via fluorescence in situ hybridization.Results: NLR was verified to be an independent prognostic marker for OS in WHO grade II and III diffuse gliomas. NLR level was also associated with OS of IDH mutant subgroup, TERT promotor mutant subgroup, 1p19q intact subgroup and with PFS of 1p19q intact subgroup. LMR level was associated with OS of WHO grade II and III diffuse gliomas and TERT promotor mutant subgroup. dNLR was verified to be an independent prognostic marker for OS in TERT promotor wild-type subgroup, 1p19q intact subgroup, IDH mutant TERT promotor wild-type 1p19q intact subgroup and for PFS of 1p19q intact subgroup. dNLR was associated with OS of WHO grade II and III diffuse gliomas and IDH mutant subgroup. 1p19q co-deletion was correlated with low NLR. Conclusion: Preoperative NLR, LMR and dNLR levels were helpful to forecast prognosis in patients with WHO grade II and III gliomas and different genetic phenotypes.

Sign in / Sign up

Export Citation Format

Share Document